31results about How to "High binding activity" patented technology

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.

The invention provides a preparation method of vitamin C, and belongs to the technical field of vitamin C. The preparation method comprises the following steps: preparing 2-keto-L-gulonic acid, preparing a catalyst and reacting. The preparation method of the catalyst comprises the following steps: carrying out water vapor treatment on a ZMS-5 molecular sieve, then putting the ZMS-5 molecular sieve into a calcining furnace, calcining at 500-520 DEG C for 3.5-5.0 h, naturally recovering to room temperature, putting the ZMS-5 molecular sieve into deionized water, adding gamma-polyglutamic acid and citric acid, uniformly stirring, filtering and drying to obtain a pretreated molecular sieve; the pretreated molecular sieve is put into a phosphoric acid solution to be soaked, drying is conducted after soaking is completed, and a catalyst is prepared; the vitamin C prepared by the preparation method disclosed by the invention is relatively high in purity and yield, and the 2-keto-L-gulonic acid prepared by fermentation is high in content and short in fermentation period.

The invention belongs to the technical field of biological medicine, and particularly relates to an iron ion carrier and a preparation method and application thereof. The iron ion carrier disclosed by the invention has the advantages that the iron ion carrier disclosed by the invention can have relatively good binding activity with iron ions and ferrous ions, and has relatively low cytotoxicity and relatively long in-vivo drug half-life period.

The invention relates to the technical field of genetic engineering antibodies, in particular to a bispecific antibody combined with BCMA and CD3 as well as a preparation method and application of the bispecific antibody. The invention provides a bispecific antibody which can be combined with BCMA and CD3 at the same time, has a specific targeting effect and can efficiently excite oriented immune response. The bispecific antibody well retains the biological functions of an anti-CD3 antibody and an anti-BCMA antibody, realizes that one bispecific antibody molecule simultaneously has an excellent BCMA and CD3 targeted binding biological function, can build a bridge between tumor cells and immune effector cells, effectively activates the immune effector cells and oriented immune response, and has a good application prospect. The tumor cell killing effect of immune cells is remarkably enhanced, the target cell killing efficiency is high, the ADCC effect is reduced to the maximum degree, high safety is achieved, and good application prospects are achieved in tumor immunotherapy.

The invention belongs to the field of biological medicine, and particularly relates to a varicella-zoster virus gB protein mutant and application thereof. According to the gB protein mutant of the varicella-zoster virus, provided by the invention, proline mutation, shearing of N-terminal and C-terminal structural domains, release of electrostatic repulsive force in the protein, mutation of a Frelin enzyme cutting site and the like are carried out in a process of converting a gB protein fusion precursor into a fusion afterbody conformation, so that the gB protein mutant of the varicella-zoster virus is obtained. The conformation before fusion can be stabilized, and the expression quantity and the stability of the antigen protein are improved. As a vaccine component, the mutant has good immunogenicity, activates autoimmunity of animals and plays a role in prevention or treatment of vaccines.

The invention relates to an RSV F protein mutant and application thereof, and belongs to the field of vaccines. On the basis of the amino acid sequence of wild RSV F protein, multiple aspects and multiple modes of modification are carried out, including disulfide bond mutation, proline mutation, cavity filling mutation, electrostatic mutation, p27 sequence modification and / or trimerization structural domain modification, and multiple RSV F protein mutants are designed. And then, through gene synthesis, expression and ELISA detection, the pre-conformation (pre-F) proportion of the RSV F protein mutants and the stability under high-temperature and low-temperature conditions are tested, and a plurality of RSV F protein mutants with relatively high pre-conformation proportion and stable structures are screened out. Finally, candidate antigen representatives are selected for immunogenicity detection, and it is proved that the candidate antigen representatives have good immunogenicity and can be used for developing RSV vaccines and preparing RSV specific antibodies or RSV detection reagents.

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The application provides an antibody against B7H6 and application thereof, the antibody comprising heavy chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 1, 2 and 3 respectively or having at least 95% identity with SEQ ID NO: 1, 2 and 3; and / or light chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 4, 5 and 6 respectively or having at least 95% identity with 4, 5 and 6. The antibody of the embodiment of the application can be combined with human and monkey B7H6 proteins, and the bispecific antibody prepared by using the antibody has higher human and monkey B7H6 binding activity, and can effectively treat and / or prevent B7H6-mediated related diseases.

The present application belongs to the field of biological medicine, and relates to an antibody or antigen-binding fragment thereof specifically binding to TAG72 and use thereof. The antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3. The anti-TAG72 specific antibody of the present application has good specific killing activity on target cells.

The invention discloses a bispecific antibody against EGFR (epidermal growth factor receptor) and c-Met (c-Met). The amino acid sequence of the Fc segment of the binding arm is modified, so that the heterodimer interaction between the EGFR binding arm and the c-Met binding arm of the bispecific antibody is stronger than the respective interaction of the EGFR binding arm and the c-Met binding arm from homodimers, and the EGFR binding arm and the c-Met binding arm can be assembled into a heterodimer in vitro; the effect of inhibiting proliferation of EGFR and c-Met double-positive tumor cells is better than that of combination of EGFR monoclonal antibody and c-Met monoclonal antibody, antibody dependent cytotoxicity (ADCC) is mediated, target protein internalization is promoted, and proliferation of osimertinib acquired drug-resistant strain cells is inhibited. The bispecific antibody prepared by the invention is simple to prepare and stable in structure, the pure bispecific antibody is obtained by in-vitro assembly, and clinical treatment requirements are expected to be better met, so that the bispecific antibody has a good market prospect.

The application belongs to the technical field of biology and specifically relates to an anti-CD25 monoclonal antibody, a preparation method thereof and application thereof. The anti-CD25 monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region VH comprises three complementarity determining regions, and the amino acid sequences are shown as SEQ ID NO: 1-3. The light chain variable region VL also comprises three complementarity determining regions, and the amino acid sequences are shown as SEQ ID NO: 4-6. The application further provides a preparation method of the anti-CD25 monoclonal antibody. The monoclonal antibody development method has the advantages of short time consumption, high throughput and high positive rate.

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.

The invention belongs to the technical field of molecular biology, and particularly relates to an anti-human TIGIT monoclonal antibody and application thereof. The anti-human TIGIT monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3; the light chain variable region comprises a VLCDR1, a VLCDR2 and a VLCDR3 of which the amino acid sequences are shown as SEQ ID NO: 4-6. The invention also provides an application of the anti-human TIGIT monoclonal antibody in tumor immunotherapy, preparation of a reagent for detecting the TIGIT protein or preparation of a product combined with the human TIGIT protein. The anti-human TIGIT monoclonal antibody has the technical effects that the novel anti-human TIGIT monoclonal antibody is obtained through screening, and the antigen binding activity of the anti-human TIGIT monoclonal antibody is better than that of the existing anti-human TIGIT monoclonal antibody. According to the antibody development method provided by the invention, the development time of the target antibody is shortened, the flux is high, the positive rate is high, and the antigen binding activity is better.

The present application provides an anti-CDH17 antibody or an antigen binding fragment thereof, which can be a bispecific antibody constructed. The anti-CDH17 antibody provided by the present application can specifically bind to CDH17 protein, has a relatively strong CDH17-expressing tumor cell killing effect, can be effectively internalized on CDH17-expressing tumor cells, and can be prepared into an ADC which can be effectively internalized on CDH17-expressing tumor cells and has high killing activity; in particular, compared with an antibody binding to a single epitope of CDH17, the bispecific antibody of the present application has more accurate and multi-dimensional antigen recognition ability and higher targeting.

The application discloses a specific antibody MR-34 targeting a coronavirus MERS-CoV spike protein RBD. Sequences of CDRs of the antibody are shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the application can specifically combine with the MERS-CoV spike protein RBD domain by containing the specific sequence of CDRs. The antibody provided by the application has high targeting property and high combining activity. The antibody prepared by the preparation method provided by the application has high purity and can be prepared in large quantities. Overall, the antibody of the application can be used for development and optimization of a MERS-CoV infection detection method.

The application discloses an anti-Western Nile virus neutralizing antibody WN-XH3 and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, has good binding activity with Western Nile virus E protein, and has strong virus neutralizing activity, thereby laying a foundation for diagnosis and treatment of Western Nile virus infection related diseases, development of a Western Nile virus infection related disease treatment drug and the like, and can be used as a candidate of a clinical anti-Western Nile virus drug, and has a good application prospect.

The application discloses a Gastrodia elata-Wolfberry extract as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine. The preparation method of the Gastrodia elata-Wolfberry extract comprises the following steps: (1) mixing Gastrodia elata and Wolfberry, crushing into powder, sieving, and obtaining a mixture powder; (2) adding water and a compound enzyme I, performing enzymolysis extraction under high-intensity ultrasonic waves with a power of 900-1800 W, obtaining a first enzymolysis liquid, centrifuging, and obtaining a first supernatant; (3) adding a compound enzyme II, performing enzymolysis extraction under high-intensity ultrasonic waves with a power of 900-1800 W, obtaining a second enzymolysis liquid, centrifuging, and obtaining a Gastrodia elata-Wolfberry extract liquid; and (4) freeze-drying to obtain the Gastrodia elata-Wolfberry extract. The compound enzyme I and the compound enzyme II are used to perform double enzymolysis on the Gastrodia elata and the Wolfberry, and high-intensity ultrasonic waves with a power of 900-1800 W are used to assist in the enzymolysis process, so that the nutritional components and effective active components in the Gastrodia elata and the Wolfberry can be effectively extracted, the enzyme consumption is reduced, and the extraction time is shortened.

Disclosed is an antigen targeting, anti-CD16A, and immune effector cell activating trifunctional fusion protein, comprising: a CD16A binding region that specifically binds to CD16A, a tumor-associated antigen (TAA) binding region that specifically binds to a TAA, an IL-15 / IL-15Rα complex formed by combining IL-15 and IL-15Ra, and an Fc domain. A designed tumor-targeting innate immune cell activation molecule, i.e., an anti-TAA, anti-CD 16A, and cytokine IL 15 trifunctional fusion protein targets NK cells to a tumor by simultaneously binding to a TAA on tumor cells and CD16A on NK cells, so that the NK cells release perforin and granzymes to induce apoptosis and cause tumor cell death. The cytokine IL15 expands and maintains the function of the NK cells, stimulates immune cell proliferation, and changes the immune microenviroment of the tumor.

The present invention provides a polypeptide comprising a heavy chain variable region (VH) domain and a light chain variable region (VL) domain linked via a peptide linker, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 1 or 2.

The present invention belongs to the technical field of antibody preparation, and in particular, relates to monoclonal antibodies, antibody pairs and kits for human cone protein-like protein 1 and their applications. The monoclonal antibody is a first antibody or a second antibody, and the amino acid sequences of CDR1-3 on the light chain of the first antibody are shown as SEQ ID NO.3-5, respectively, and the amino acid sequences of CDR1-3 on the heavy chain are shown as SEQ ID NO.8-10, respectively; the amino acid sequences of CDR1-3 on the light chain of the second antibody are shown as SEQ ID NO.13-15, respectively, and the amino acid sequences of CDR1-3 on the heavy chain are shown as SEQ ID NO.18-20, respectively. The antibody of the present invention has high binding activity and affinity to human VILIP-1 protein, and can form a double antibody sandwich enzyme-linked immunosorbent assay system to achieve specificity, sensitivity, reliability and accuracy detection of extremely trace levels of VILIP-1 in samples.

The present invention provides a complex comprising a ligand, a spacer, and a peptide linker, which is useful for in vivo diagnostic drugs and internal irradiation therapy, using an anti-human MUC1 antibody Fab fragment whose binding activity is not reduced by labeling with a metal, a fluorescent dye, etc. The complex comprising three-arm DOTA, a specific spacer, a specific peptide linker, and a biomolecule including an anti-human MUC1 antibody Fab fragment has a binding activity that is not reduced by labeling with a metal, a fluorescent dye, etc., and can be used as a diagnostic composition and / or a pharmaceutical composition.

The invention discloses a traditional Chinese medicine composition for treating hypoxic pulmonary hypertension and a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. The traditional Chinese medicine composition comprises the following raw material medicines: choerospondias axillaris, myristica fragrans, sandalwood, salvia miltiorrhiza, ligusticum wallichii, angelica sinensis, codonopsis pilosula, cistanche deserticola, semen cuscutae, astragalus membranaceus, rhodiola rosea and herba epimedii. The traditional Chinese medicine composition disclosed by the invention is mainly used for regulating and controlling proliferation and migration processes of pulmonary artery smooth muscle cells and pulmonary artery endothelial cells and reaction to hypoxia and inflammation through multiple targets and multiple paths. Molecular docking results show that the core components of the traditional Chinese medicine composition and core intersection targets have good binding activity, molecular dynamics simulation verifies the molecular docking results, and the related action mechanism is clear. And meanwhile, through network pharmacology research, more choices and discussion bases are provided for clinical prescription application.

The present invention relates to a poxvirus human neutralizing antibody MV129 or an antigen-binding fragment thereof and its application, which comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequences of CDR1H, CDR2H and CDR3H of the heavy chain variable region are shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively; the amino acid sequences of CDR1L, CDR2L and CDR3L of the light chain variable region are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The neutralizing antibody MV129 of the present invention can bind to the A35 antigen of MPXV and also has good neutralizing activity against the MPXV true virus.

The present invention provides an anti-CD94 antibody and its application, the antibody comprises heavy chain CDR1, CDR2 and CDR3, and light chain CDR1, CDR2 and CDR3; wherein: the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 have at least 80% homology with the sequences shown in SEQ ID NO: 1, 2, 3, respectively, and the amino acid sequences of the light chain CDR1, CDR2 and CDR3 have at least 80% homology with the sequences shown in SEQ ID NO: 4, 5, 6, respectively. The antibody of the embodiment of the present invention can bind to the human CD94 protein, relieve CD94 / NKG2A-mediated immunosuppression, promote T cell activation, and can effectively treat and / or prevent CD94-mediated related diseases.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-Trop2 nanobody and application thereof. The application provides an anti-Trop2 nanobody, and an amino acid sequence of the anti-Trop2 nanobody is SEQ ID NO. 4. The anti-Trop2 nanobody provided by the application has specific recognition and binding capacity, and application thereof is related to diagnosis and treatment of Trop2 related tumor diseases, basic medical research, biological research and the like, and has wide biological application and clinical application value.

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.

The invention discloses a wear-resistant material for sealing a high-speed rotating part and a preparation method thereof, the wear-resistant material is applied to a friction working area between the rotating part and a static part, and the wear-resistant material comprises the following components in parts by weight: 40-60 parts of silicon carbide, 10-30 parts of hydroxylated modified polyether-ether-ketone, 3-10 parts of composite fiber, 5-15 parts of magnesium lithium silicate sol and 1-2 parts of a silane coupling agent. The wear-resistant material can be applied to media such as sewage with high impact pressure and chemical waste liquid, the surface of the wear-resistant material is not prone to cracking, the wear resistance is excellent, and it is helpful for keeping a high-speed rotating part to have a long service life.

The invention provides a method for catalyzing an alpha, beta, gamma, delta-unsaturated ketone chiral boron addition reaction through a nano-composite microsphere supported copper material, and belongs to the technical field of asymmetric catalyst.The method comprises the following steps that in a reaction solvent, alpha, beta, gamma, delta-unsaturated ketone chiral boron addition reaction is carried out, and alpha, beta, gamma, delta-unsaturated ketone chiral boron addition reaction is carried out; the preparation method comprises the following steps: carrying out chiral boron addition reaction on beta, delta-unsaturated ketone and B2 (pin) 2 under the action of a nano-composite microsphere loaded copper material and a chiral ligand to obtain a 1, 4-chiral boron compound; a carrier of the nano-composite microsphere loaded copper material is a PS-CS-SiO2 nano-composite microsphere, the PS-CS-SiO2 nano-composite microsphere is composed of PS monodisperse microsphere powder, SiO2 and chitosan, and an active component Cu < 2 + > is loaded on the PS-CS-SiO2 nano-composite microsphere. 3-7 mg of the nano composite microsphere loaded copper material is added into every 0.2 mmol of alpha, beta, gamma, delta-unsaturated ketone. The nano-composite microsphere loaded copper material is used as a catalyst to catalyze alpha, beta, gamma, delta-unsaturated ketones to perform chiral boron addition reaction, and the nano-composite microsphere loaded copper material is used as a novel catalytic material, can be recycled, and is green and environment-friendly.

The present invention relates to the field of monoclonal antibodies, and specifically to monkeypox virus A29L monoclonal antibodies, kits and applications. The monkeypox virus A29L monoclonal antibody comprises a heavy chain and a light chain, the amino acid sequence of the heavy chain is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain is shown in SEQ ID NO: 14; or the amino acid sequence of the heavy chain is shown in SEQ ID NO: 15, and the amino acid sequence of the light chain is shown in SEQ ID NO: 16. The present invention also provides a kit comprising a monkeypox virus A29L monoclonal antibody or a conjugate thereof, and provides the use of the monkeypox virus A29L monoclonal antibody or the kit in detecting monkeypox virus or preparing a product for detecting monkeypox virus. The monoclonal antibody in the present invention has high purity, high binding activity with monkeypox virus A29L, and good specificity; it has high sensitivity for detecting monkeypox virus A29L, a wide linear range, and a minimum detection concentration of 37.8 pg / mL; it lays a foundation for establishing an immunological detection method for monkeypox virus.

The present invention relates to antibodies or antigen-binding fragments thereof for detecting thyroxine, and related protein products, nucleic acid products, cell products, detection reagents, and preparation methods and applications thereof. The antibody for detecting thyroxine of the present invention is an antibody for an immune complex containing thyroxine, which can bind to a thyroxine antigen-antibody immune complex as an immunogen with high specificity and high affinity, without binding to a single thyroxine and an anti-thyroxine antibody in the immune complex, and therefore, it can be used in combination with the anti-thyroxine antibody in the immune complex for immunological detection of thyroxine, and the immunological detection based on the two antibodies has high detection accuracy and sensitivity, thereby breaking through the limitations of low sensitivity and poor clinical relevance of traditional competitive detection reagents, and is of great significance for the early diagnosis and treatment of thyroid diseases.